Advaxis looking to partner

7 May 2009

New Jersey, USA-based Advaxis has entered into a formal business agreement with the Sage Group to introduce potential partnership  candidates and develop new licensing opportunities. The Sage Group is a  provider of strategic and transactional consultancy services to US and  European health care and life science companies advising on global  strategic partnering opportunities.

"With the increasing acceptance of our technology in the experimental  medical community, it is an opportune time to identify possible  strategic relationships," noted Advaxis chief executive Thomas Moore.  "As our current licensing negotiations develop, we also seek to find  additional opportunities to commercialize our platform as expeditiously  as possible, and the Sage Group's expertise will help us find the best  fit among potential partners, both near and long term," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight